Navigation Links
Women undergoing PCI display greater number of co-morbidities than men
Date:10/31/2011

New research shows that women undergoing percutaneous coronary intervention (PCI), also known as angioplasty, exhibit more co-morbidities and cardiovascular risk factors than men. Risk-adjusted analyses have now indicated that, in the contemporary era, gender is not an independent mortality predictor following PCI according to the study now available in Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

Each year more than one million Americans undergo PCI to open blocked arteries according to the National Heart, Lung and Blood Institute. Prior studies have given conflicting reports regarding the outcomes of females versus males after PCI, with some suggesting women have poorer outcomes compared to men and others finding little or no difference. This contradiction in results has remained under dispute, with some experts suggesting that improved PCI techniques, modification of risk-factors and pharmacological advances may balance adverse outcomes between the genders.

To clarify these gender differences, Annapoorna Kini, MD, and colleagues from Mount Sinai Hospital in New York, explored PCI outcomes in a racially diverse patient group at a high-volume, tertiary hospital. The team identified 4761 female and 8991 male patients at their institution who underwent PCI between April 2003 and 2009. Information including clinical characteristics, procedural details, laboratory and diagnostic test results, as well as 30-day and 1-year follow-up data, was collected.

"Our findings extend previous research, and definitively show that following PCI, women do not have an inherently greater mortality risk compared to men," explains Dr. Kini. "However, we did find that prognostic risk factors were significantly more prevalent in women." Results showed that compared to men, females were older, and were more likely to have hypertension, diabetes, and higher LDL cholesterol levels. Kini added, "While men did have higher rates of some modifiable risk-factors, such as smoking, women certainly had a far greater overall burden of co-morbidities and adverse prognostic factors." The data showed that a greater number of women also presented with an unstable coronary syndrome.

In the key findings of this study, the unadjusted post-PCI mortality rate was higher in women compared with men, with 30-day rates of 1.3% versus 0.8%; one-year at 6.1% versus 4.8%; and three-year at 10.4% versus 8.4%. Adjusted modeling, however, which accounted for the gender-imbalance in risk factors, proved that women were not at higher mortality risk than men following PCI in this racially diverse group. Dr. Kini concluded, "While our study found no risk-adjusted difference in mortality between men and women, both sexes would benefit from attention to modifying factors that reduce the risk of heart diseaseeliminating smoking, engaging in physical activity, and eating a healthy diet."

The Centers for Disease Control and Prevention (CDC) reports that heart disease is the leading cause of death among men and women, killing more than one in every four Americans.


'/>"/>
Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Company Invites Women to STOP PMS - Take the 10-Minute Challenge
2. LifestyleMom.com and the LifestyleMom Radio Cafe Aim to Help Women Create a Family Life and "Me Life" That They Truly Love
3. Women More Likely to Fail Treatment for Atrial Fibrillation
4. Diabetes drug ups risk for bone fractures in older women
5. Womens Heart Disease Awareness Still Lacking
6. Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV
7. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
8. Womens Dermatologic Society Marks 35th Anniversary with Release of Unprecedented Book of Wisdom and Inspiration
9. Few Women at High Risk for Breast Cancer Take Tamoxifen
10. Diane von Furstenberg Establishes The DVF Awards to Recognize Outstanding Women Leaders
11. YazTalk Warns Women of Life Threatening Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited to ... water brand owners that topped the list as a result of their commitment to ... premier brand was Tibet 5100, a top notch water company that specializes in providing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Resolve Therapeutics, LLC, a clinical stage biopharmaceutical ... treatment of lupus and Sjogrens syndrome, today announced ... study in patients with systemic lupus erythematosus (SLE) ... --> --> Data from a ... of RSLV-132 in 32 subjects with SLE demonstrate ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... A Worldwide Clinical Trials expert will present at ... Plaza in London , 24-25 February 2016. ... advances for late phase research on Wednesday, 24 Feb at ... director of project management at Worldwide, will focus on how ... standards in late phase research. --> ...
Breaking Medicine Technology: